Sign in
CompletedNo phase

The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL

Key facts

Who runs it
University of Roehampton
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
20 people enrolled
Started
10 Dec 2025
Ended
15 Jun 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Personalized prebiotic dietary Formulation 2
  • Personalized prebiotic dietary Formulation 3
  • Personalized prebiotic dietary Formulation 1
Record updated
20 October 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (18)Hide the full registry criteria

Who can take part

  • Adults aged approximately 18-65 years
  • Male or female
  • Generally in good health, with no significant chronic illnesses
  • Resident in the UK (to enable centralized ethics oversight and logistics)
  • Able to re and understand English (for e-consent and study instructions)
  • Mild to moderate alcohol consumption (more than 14 units or 6 pints per week)
  • Willing to provide stool samples at the required time points
  • Willing to take a daily prebiotic supplement for 60 days
  • Has access to the internet and email for remote communication
  • Able and willing to provide informed electronic consent

Who cannot take part

  • Use of special diets or medications that significantly alter gut microbiota (e.g., chronic laxative use, immunosuppressive therapy)
  • Any known significant gastrointestinal disease (e.g., inflammatory bowel disease, celiac disease)
  • Any major medical condition that could affect the gut microbiome or pose a health risk (e.g., immunocompromised conditions)
  • Known allergies or intolerances to components likely used in the prebiotic formulation (e.g., certain amino acids)
  • Recent use of antibiotics (within the past 2-3 months)
  • Recent regular use of probiotics or prebiotics (within approximately the past 4 weeks)
  • Pregnant or breastfeeding women (pregnancy will be screened at enrolment, as the intervention is not tested during pregnancy and pregnancy itself alters the gut microbiome)
  • Participation in another interventional clinical trial within the past 3 months

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The human gut contains a vast community of microorganisms-including bacteria, viruses, and fungi-collectively known as the gut microbiota. This ecosystem co-evolves with humans and is shaped by diet, environment, and lifestyle. A balanced microbiota is essential for health, supporting immune function, regulating metabolism, and controlling intestinal inflammation. When this balance, or homeostasis, is disrupted, dysbiosis can occur, which has been linked to conditions such as inflammatory bowel disease, obesity, type 2 diabetes, cardiovascular disease, cancers, and neurological disorders. Evidence also shows that substance abuse can induce dysbiosis by altering microbial diversity, disrupting microbial composition, and reducing levels of key metabolites like short-chain fatty acids. Growing research on the gut-brain axis suggests that these microbial imbalances may influence mental health by affecting neurochemical signalling, contributing to disorders such as depression and anxiety. While synthetic drugs remain central to modern medicine and provide targeted, effective treatments, they often fall short when illnesses stem from disturbances within the microbial ecosystem. Because many conditions related to gut dysbiosis are not caused by a single malfunctioning molecule, traditional drugs may manage symptoms without restoring microbial balance. Some treatments, particularly broad-spectrum antibiotics, may even exacerbate dysbiosis by eliminating beneficial microbes. This has led to increasing interest in probiotics, prebiotics, and postbiotics. Probiotics are beneficial live microbes, prebiotics are non-digestible compounds that help these microbes grow, and postbiotics are their health-promoting byproducts. Although promising, these interventions are still considered supplements rather than formal medicines. Studying stool samples allows researchers to assess gut health by measuring bacterial and metabolic contents. Advances in this field require precise, efficient tools. Perseus Biomics' DynaMAP™ technology enables strain-level microbiome profiling. This study aims to validate DynaMAP™ against shotgun metagenomic sequencing and assess personalized prebiotic interventions based on individual microbiome profiles.

The 3 groups in the trial

  • Personalized prebiotic dietary Formulation 1Existing treatment, for comparison

    A nutritional prebiotic supplement tailored to their microbiome profile as to take daily for 60 days

  • Personalized prebiotic dietary Formulation 2Existing treatment, for comparison

    A nutritional prebiotic supplement tailored to their microbiome profile as to take daily for 60 days

  • Personalized prebiotic dietary Formulation 3Existing treatment, for comparison

    A nutritional prebiotic supplement tailored to their microbiome profile as to take daily for 60 days

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pilot Exploratory Investigation Into DynaMAP Validation, Gut Microbiome Profiling, and Personalized Prebiotic Interventions for Alcohol Addiction Recovery
Record updated
20 October 2026